DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The Dexcom G7 15 Day ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
However, Oppenheimer downgraded DexCom from Outperform to Perform, pointing to ongoing accuracy and performance challenges with the G7 device. Adding to the concerns, Hunterbrook Media released a ...
In other recent news, DexCom has been the focus of various analyst reports and market reactions regarding its G7 continuous glucose monitoring device. UBS maintained its Buy rating for DexCom, setting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results